NCT06563713View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STSP-0902 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

February 24, 2025

Study Completion Date

February 24, 2025

Conditions
OligozoospermiaAsthenozoospermia
Interventions
DRUG

STSP-0902 injection

Subjects will receive the administration dose on Day 0 following protocol requirements

DRUG

Placebo

Subjects will receive the administration dose on Day 0 following protocol requirements

Trial Locations (1)

100191

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Staidson (Beijing) Biopharmaceuticals Co., Ltd

INDUSTRY

NCT06563713 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STSP-0902 in Healthy Subjects | Biotech Hunter | Biotech Hunter